Owen Hughes - 14 Sep 2021 Form 4 Insider Report for Translate Bio, Inc.

Role: Director
Signature: /s/ Paul D. Burgess, as attorney-in-fact for Owen Hughes
Issuer symbol: N/A
Transactions as of: 14 Sep 2021
Net transactions value: -$1,134,680
Form type: 4
Filing time: 14 Sep 2021, 19:26:06 UTC
Previous filing: 16 Jun 2021
Next filing: 30 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBIO	Common Stock	Sale	$1,134,680	-29,860	-100%	$38.00^*	0	14 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-38,135	-100%	$0.000000^*	0	14 Sep 2021	Common Stock	38,135	$7.39	Direct	F2, F3
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-18,900	-100%	$0.000000^*	0	14 Sep 2021	Common Stock	18,900	$10.20	Direct	F2, F4
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-18,900	-100%	$0.000000^*	0	14 Sep 2021	Common Stock	18,900	$15.33	Direct	F2, F5
transaction	TBIO	Stock Option (righ to buy)	Sale	$0	-20,000	-100%	$0.000000^*	0	14 Sep 2021	Common Stock	20,000	$20.43	Direct	F2, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
F2	Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F3	The shares underlying this option became fully vested on March 9, 2021.
F4	This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
F5	This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
F6	This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.